

CLAIMS

We claim:

1. A pharmaceutical composition comprising at least one peptide selected from the group consisting of DP2 D-A13, DP3 D-HA3G76, DP4 D-A4G82, DP5 D-A5G81, DP6
5 D-A5G101, DP7 D-HA3G47, DP8 D-HA3G58, DP9 D-HA3G74, DP10 D-HA3G83, DP11 D-A5G82, DP13 D-R-AG73, DP14 D-R-A13, DP15 D-R-HA3G76, DP16 D-R-A4G82, and DP17 D-R-A5G81.
2. The pharmaceutical composition of Claim 1 wherein the at least one peptide selected from the subgroup consisting of DP2 D-A13, DP4 D-A4G82, DP5 D-A5G81, DP6
10 D-A5G101, DP8 D-HA3G58, DP10 D-HA3G83, DP14 D-R-A13, DP15 D-R-HA3G76 and DP16 D-R-A4G82.
3. The pharmaceutical composition of Claim 1 wherein individual amino acids of the laminin peptide may be either L- or D-amino acids.
4. The pharmaceutical composition of Claim 1 further comprising a therapeutically
15 effective amount of a pharmaceutically acceptable carrier, diluent or excipient.
5. A pharmaceutical agent comprising a therapeutically effective amount of a peptide selected from the group consisting of DP2 D-A13, DP3 D-HA3G76, DP4 D-A4G82, DP5 D-A5G81, DP6 D-A5G101, DP7 D-HA3G47, DP8 D-HA3G58, DP9 D-HA3G74, DP10 D-HA3G83, DP11 D-A5G82, DP13 D-R-AG73, DP14 D-R-A13, DP15 D-R-HA3G76, DP16
20 D-R-A4G82, and DP17 D-R-A5G81, the peptide selected for efficacy in treating A β amyloidosis in a patient.
6. The pharmaceutical agent of claim 5 wherein the polypeptide is comprised of both L- and D-amino acids.
7. The pharmaceutical agent of claim 5 further comprising a pharmaceutically
25 acceptable carrier, diluent or excipient.
8. The pharmaceutical agent of claim 5 wherein the therapeutically effective amount is selected such that it has an A β amyloid inhibitory activity or efficacy in greater than 30% in the patient.
9. The pharmaceutical agent of claim 8 wherein the therapeutically effective amount
30 is selected such that it has an A β amyloid inhibitory activity or efficacy in greater than 50% in the patient.

10. The pharmaceutical agent of claim 9 wherein the therapeutically effective amount is selected such that it has an A β amyloid inhibitory activity or efficacy in greater than 90% in the patient.
- 5 11. The pharmaceutical agent of claim 5 wherein said A β amyloidosis is Alzheimer's disease.
12. The pharmaceutical agent of claim 5 wherein the therapeutically effect amount of peptide comprises a dosage in the range of from about 10 μ g to about 50 mg/kg body weight/per day.
- 10 13. The pharmaceutical agent of claim 12 wherein the therapeutically effect amount of peptide comprises a dosage in the range of from about 100 μ g to about 10 mg/kg body weight per day.
14. The pharmaceutical agent of claim 5 wherein the therapeutically effective amount of peptide is administered in a parenterally injectable or infusible form.
- 15 15. The pharmaceutical agent of claim 5 wherein the therapeutically effective amount of peptide is administered orally.